Reckitt's Indivior endeavors to 'gain recognition for addiction,' says CEO
This article was originally published in Scrip
Executive Summary
UK consumer goods firm Reckitt Benckiser plans to list shares of its addiction-focused pharmaceutical spin off Indivior on 23 December on the London Stock Exchnage, subject to approval at a shareholder meeting on 11 December.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.